QRxPharma Limited has submitted a New Drug Application (NDA) for MoxDuo IR for the treatment of moderate to severe acute pain. This NDA submission is based on a full clinical and manufacturing program for MoxDuo IR. The development program included three pivotal Phase 3 studies for the treatment of moderate to severe post-operative pain. Clinical data have consistently demonstrated that MoxDuo IR achieves equal or better pain relief with fewer incidences of moderate to severe side effects in head-to-head comparisons with morphine, oxycodone, Percocet and placebo.

MoxDuo IR comes in a capsule formulation in a 3:2 fixed ratio combination of morphine and oxycodone. 

For more information call (908) 506-2900 or visit www.qrxpharma.com.